Ilja Tchetverikov Selected Research

Methotrexate (Mexate)

1/2020

Achieving sustained minimal disease activity with methotrexate in early interleukin 23-driven early psoriatic arthritis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ilja Tchetverikov Research Topics

Disease

2	Rheumatoid Arthritis 01/2019 - 01/2018
1	Back Pain (Backache) 02/2024
1	Arthritis (Polyarthritis) 12/2022
1	Synovitis 10/2022
1	Psoriatic Arthritis 01/2020
1	Pain (Aches) 01/2018
1	Fatigue 01/2018
1	Sarcoidosis (Schaumann Disease) 03/2014
1	Osteoarthritis 02/2003
1	Disease Progression 09/2002

Drug/Important Bio-Agent (IBA)

2	Tumor Necrosis Factor InhibitorsIBA 01/2019 - 01/2018
1	C-Reactive ProteinIBA 02/2024
1	Antirheumatic Agents (DMARD)IBA 12/2022
1	IMB 10IBA 10/2022
1	InterleukinsIBA 01/2020
1	Methotrexate (Mexate)FDA LinkGeneric 01/2020
1	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 03/2014
1	Cartilage Oligomeric Matrix ProteinIBA 02/2003
1	ThrombospondinsIBA 02/2003

Therapy/Procedure

2	Therapeutics 01/2020 - 09/2002